| Literature DB >> 35541365 |
Weiwei Rong1, Kewen Ding1, Sirui Guo1, Ziyue Yuan1, Qing Li1, Kaishun Bi1.
Abstract
Xanthoceras sorbifolia Bunge is a folk medicine in China. Recently, the triterpenoids in its husks have attracted more and more attention for potential prevention against Alzheimer's disease. However, current studies on its bioactive substances were still insufficient. To reveal more bioactive substances, an efficient and practical strategy based on high resolution mass spectra coupled with multiple data mining techniques was developed to characterize the barrigenol type triterpenoids in the husks and dosed rat plasma. A total of 50 barrigenol type triterpenoids were identified in the husks, and 6 of these were detected in the rat plasma, which were regarded as bioactive candidates. To find the real bioactive substances, the neuroprotective effect of the candidates was further tested by calculating the PC12 cell viability against amyloid-β-induced cytotoxicity. As a result, three out of the six candidates exhibited obvious neuroprotction against amyloid-β-induced cytotoxicity on PC12 cells, indicating their potential to be bioactive substances against Alzheimer's disease. This study will be a valuable reference of the bioactive substances in Xanthoceras sorbifolia Bunge husks against Alzheimer's disease and the provided strategy can also be applied to the exploration of the effective constituents in other medicines. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35541365 PMCID: PMC9079961 DOI: 10.1039/c8ra01765d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structures of barrigenol triterpenoids in X. sorbifolia.*: reference standards of barrigenol type triterpenoids.
Fig. 2The characteristic fragment pathways of barrigenol triterpenoids in X. sorbifolia husks. (A): R1-Barrigenol triterpenoid saponin (compound 33); (B): barringtogenol C triterpenoid saponin (compound 40); (C): 16-dexoybarringtogenol C triterpenoid saponin (compound 10).
Fig. 3MTT result in PC12 validation test. Y-axis, cell viability (%); X-axis, the order from left to right: control (100%), model (Aβ25–35, 20 μM), the concentration gradient of the test samples (0.005 mg ml−1; 0.01 mg ml−1; 0.05 mg ml−1 and 0.1 mg ml−1), the concentration of huperzine-A (0.242 × 10−3 mg ml−1). (A): Compound 33; (B): compound 10; (C): compound 17. *p < 0.05 and **p < 0.01 vs. control; #p < 0.05 and ##p < 0.01 vs. model.